These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34007904)

  • 21. Financial costs associated with monopolies on biologic medicines in Australia.
    Gleeson D; Townsend B; Lopert R; Lexchin J; Moir H
    Aust Health Rev; 2019 Feb; 43(1):36-42. PubMed ID: 29116927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010.
    Handelsman DJ
    Med J Aust; 2012 Jun; 196(10):642-5. PubMed ID: 22676880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Financial contributions made by patients towards dispensed medicines prescribed by Australian dentists from 2006 to 2018: a cost-analysis study.
    Park JS; Kruger E; Tennant M
    Aust Health Rev; 2021 Mar; 45(2):167-172. PubMed ID: 33176901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacovigilance in pregnancy using population-based linked datasets.
    Colvin L; Slack-Smith L; Stanley FJ; Bower C
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):211-25. PubMed ID: 19173342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a state hospital formulary on medicines utilisation in Australia.
    Iedema J
    Aust Health Rev; 2021 Dec; 45(6):704-717. PubMed ID: 34743785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dispensing Patterns of Blood Pressure Lowering Agents in Older Australians From 2006 to 2016.
    Si S; Ofori-Asenso R; Briffa T; Ilomaki J; Sanfilippo F; Reid CM; Liew D
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):242-250. PubMed ID: 30463435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in opioid utilisation in Australia, 2006-2015: Insights from multiple metrics.
    Karanges EA; Buckley NA; Brett J; Blanch B; Litchfield M; Degenhardt L; Pearson SA
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):504-512. PubMed ID: 29280224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent trends in the use of linked data in Australia.
    Young A; Flack F
    Aust Health Rev; 2018 Sep; 42(5):584-590. PubMed ID: 30145995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nationwide study of multimedicine use in people treated with cardiovascular medicines in Australia.
    Schaffer AL; Chia J; Brett J; Pearson SA; Falster MO
    Pharmacotherapy; 2022 Nov; 42(11):828-836. PubMed ID: 36239072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia.
    Seaman KL; Sanfilippo FM; Roughead EE; Bulsara MK; Kemp-Casey A; Bulsara C; Watts GF; Preen D
    BMJ Open; 2017 Jun; 7(6):e013691. PubMed ID: 28637723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
    Lu CY; Williams KM; Day RO
    Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study.
    Brett J; Elshaug AG; Bhatia RS; Chalmers K; Badgery-Parker T; Pearson SA
    Implement Sci; 2017 May; 12(1):58. PubMed ID: 28468629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoepidemiology and costs of medications dispensed during pregnancy: A retrospective population-based study.
    Jackson H; Grzeskowiak LE; Enticott J; Callander E
    BJOG; 2023 Oct; 130(11):1317-1327. PubMed ID: 37039252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescription opioid analgesics for pain management in Australia: 20 years of dispensing.
    Islam MM; McRae IS; Mazumdar S; Taplin S; McKetin R
    Intern Med J; 2016 Aug; 46(8):955-63. PubMed ID: 26602489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in opioid prescribing in Australia: a systematic review.
    Donovan PJ; Arroyo D; Pattullo C; Bell A
    Aust Health Rev; 2020 Apr; 44(2):277-287. PubMed ID: 32241339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis.
    Daniels B; Schaffer A; Buckley NA; Bruno C; Jun M; Pearson SA; Zoega H
    Pharmacoepidemiol Drug Saf; 2022 Mar; 31(3):370-378. PubMed ID: 34894368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engaging stakeholders in pharmacoepidemiology research: Current state and recommendations.
    Camelo Castillo W; Heath N; Kim J; Yang K; Ritchey ME; dosReis S; Santanello N; West SL
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):766-776. PubMed ID: 31050092
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.